Corbus Pharmaceuticals announced a restructuring of its workforce designed to reallocate capital to certain clinical and preclinical programs. The restructuring will result in a reduction of its workforce by 54%.
Corbus Pharmaceuticals said that anabasum achieved the primary endpoint of a Phase II study in patients with cystic fibrosis, with the experimental drug displaying an acceptable safety and tolerability profile at all examined doses with no serious or seve